Free Trial
OTCMKTS:CVALF

Covalon Technologies 2/21/2025 Earnings Report

Covalon Technologies logo
$1.98 +0.07 (+3.48%)
As of 07/11/2025 02:59 PM Eastern

Covalon Technologies EPS Results

Actual EPS
$0.03
Consensus EPS
-$0.03
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Covalon Technologies Revenue Results

Actual Revenue
$5.84 million
Expected Revenue
$6.37 million
Beat/Miss
Missed by -$526.00 thousand
YoY Revenue Growth
N/A

Covalon Technologies Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Covalon Technologies' next earnings date is estimated for Tuesday, August 19, 2025, based on past reporting schedules.

Conference Call Resources

Covalon Technologies Earnings Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Covalon Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Covalon Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Covalon Technologies and other key companies, straight to your email.

About Covalon Technologies

Covalon Technologies (OTCMKTS:CVALF) (OTCMKTS:CVALF) is a Canadian life sciences company specializing in the development and commercialization of infection prevention and wound care technologies. The company’s core competencies lie in advanced antimicrobial coatings, biocompatible wound dressings and medical device technologies designed to reduce the risk of infection in surgical and acute care settings. Covalon’s product pipeline includes implantable antimicrobial coatings for orthopaedic and reconstructive devices, transparent wound care dressings that deliver targeted antimicrobial agents, and advanced catheter coatings engineered to combat central line–associated bloodstream infections.

Founded in 2001 and headquartered in Vancouver, British Columbia, Covalon has expanded its global footprint with commercial operations across North America, Europe and select markets in Asia. The company leverages a network of distributors and strategic partnerships to bring its proprietary technologies into hospitals, clinics and specialty care centers. Its manufacturing facilities conform to ISO 13485 standards, and its regulatory clearances span Health Canada, the U.S. Food and Drug Administration and the European CE marking process.

Under the guidance of an executive team with extensive expertise in biomedical engineering, regulatory affairs and medical device commercialization, Covalon continues to advance its research programs and pursue opportunities in emerging wound care markets. The leadership’s focus on strategic collaborations and intellectual property development positions the company to address unmet clinical needs and to drive long-term growth in infection prevention and wound management sectors.

View Covalon Technologies Profile

More Earnings Resources from MarketBeat